These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36352410)

  • 21. Shift in harms and benefits of cervical cancer screening in the era of HPV screening and vaccination: a modelling study.
    Kaljouw S; Jansen EEL; Aitken CA; de Kok IMCM
    BJOG; 2022 Oct; 129(11):1862-1869. PubMed ID: 35429107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identifying a Single Optimal Integrated Cervical Cancer Prevention Policy in Norway: A Cost-Effectiveness Analysis.
    Portnoy A; Pedersen K; Nygård M; Trogstad L; Kim JJ; Burger EA
    Med Decis Making; 2022 Aug; 42(6):795-807. PubMed ID: 35255741
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Projections up to 2100 and a budget optimisation strategy towards cervical cancer elimination in China: a modelling study.
    Xia C; Hu S; Xu X; Zhao X; Qiao Y; Broutet N; Canfell K; Hutubessy R; Zhao F
    Lancet Public Health; 2019 Sep; 4(9):e462-e472. PubMed ID: 31493843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact and cost-effectiveness of strategies to accelerate cervical cancer elimination: A model-based analysis.
    Portnoy A; Pedersen K; Trogstad L; Hansen BT; Feiring B; Laake I; Smith MA; Sy S; Nygård M; Kim JJ; Burger EA
    Prev Med; 2021 Mar; 144():106276. PubMed ID: 33678239
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Projected time to elimination of cervical cancer in the USA: a comparative modelling study.
    Burger EA; Smith MA; Killen J; Sy S; Simms KT; Canfell K; Kim JJ
    Lancet Public Health; 2020 Apr; 5(4):e213-e222. PubMed ID: 32057315
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of updated demography, disability weights, and cervical cancer burden on estimates of human papillomavirus vaccination impact at the global, regional, and national levels: a PRIME modelling study.
    Abbas KM; van Zandvoort K; Brisson M; Jit M
    Lancet Glob Health; 2020 Apr; 8(4):e536-e544. PubMed ID: 32105613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis.
    Simms KT; Laprise JF; Smith MA; Lew JB; Caruana M; Brisson M; Canfell K
    Lancet Public Health; 2016 Dec; 1(2):e66-e75. PubMed ID: 29253419
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
    Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
    Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and economic impact of school-based nonavalent human papillomavirus vaccine on women in Singapore: a transmission dynamic mathematical model analysis.
    Tay SK; Hsu TY; Pavelyev A; Walia A; Kulkarni AS
    BJOG; 2018 Mar; 125(4):478-486. PubMed ID: 29266694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Achieving cervical cancer elimination: The simulated impacts of HPV vaccination and transitioning from liquid-based cytology to HPV-based screening test.
    Balqis-Ali NZ; Anis-Syakira J; Fun WH; Mohd Said Z; Abdul Samad S; Zainal Abidin N; Zulkepli J; Ahmad N; Mohd Abas MN; Yong CM; Yusof SN; Daud NA; Sararaks S
    PLoS One; 2024; 19(7):e0307880. PubMed ID: 39052665
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What cervical screening is appropriate for women who have been vaccinated against high risk HPV? A simulation study.
    Landy R; Windridge P; Gillman MS; Sasieni PD
    Int J Cancer; 2018 Feb; 142(4):709-718. PubMed ID: 29023748
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Consensus Project: Participation in cervical cancer screening by the first cohorts of girls offered HPV vaccination at age 15-16 years in Italy.
    Visioli CB; Giorgi Rossi P; Armaroli P; Iossa A; Rizzolo R; Bonelli LA; Venturino E; Carozzi FM; Bisanzi S; De Marco L; Giordano L; Camussi E; Del Mistro A; Zappa M
    J Med Screen; 2023 Sep; 30(3):142-149. PubMed ID: 36999190
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa.
    Kim JJ; Campos NG; O'Shea M; Diaz M; Mutyaba I
    Vaccine; 2013 Dec; 31 Suppl 5():F60-72. PubMed ID: 24331749
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modelling cervical cancer elimination using single-visit screening and treatment strategies in the context of high HIV prevalence: estimates for KwaZulu-Natal, South Africa.
    Rao DW; Bayer CJ; Liu G; Chikandiwa A; Sharma M; Hathaway CL; Tan N; Mugo N; Barnabas RV
    J Int AIDS Soc; 2022 Oct; 25(10):e26021. PubMed ID: 36225139
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
    Demarteau N; Van Kriekinge G; Simon P
    Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program.
    Lew JB; Simms KT; Smith MA; Hall M; Kang YJ; Xu XM; Caruana M; Velentzis LS; Bessell T; Saville M; Hammond I; Canfell K
    Lancet Public Health; 2017 Feb; 2(2):e96-e107. PubMed ID: 29253402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selecting a mix of prevention strategies against cervical cancer for maximum efficiency with an optimization program.
    Demarteau N; Breuer T; Standaert B
    Pharmacoeconomics; 2012 Apr; 30(4):337-53. PubMed ID: 22409292
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estimating the effect of HIV on cervical cancer elimination in South Africa: Comparative modelling of the impact of vaccination and screening.
    Boily MC; Barnabas RV; Rönn MM; Bayer CJ; van Schalkwyk C; Soni N; Rao DW; Staadegaard L; Liu G; Silhol R; Brisson M; Johnson LF; Bloem P; Gottlieb S; Broutet N; Dalal S
    EClinicalMedicine; 2022 Dec; 54():101754. PubMed ID: 36583170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States.
    Kim JJ; Goldie SJ
    BMJ; 2009 Oct; 339():b3884. PubMed ID: 19815582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brief Report: Modeling the Impact of Voluntary Medical Male Circumcision on Cervical Cancer in Uganda.
    Davis SM; Habel MA; Pretorius C; Yu T; Toledo C; Farley T; Kabuye G; Samuelson J
    J Acquir Immune Defic Syndr; 2021 Mar; 86(3):323-328. PubMed ID: 33136817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.